PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation is a surgical robotics company dedicated to advancing patient care through transformative solutions in urology. The company's mission is to revolutionize benign prostatic hyperplasia (BPH) treatment globally by partnering with urologists to deliver best-in-class robotic solutions that positively impact patients and drive value. Headquartered in San Jose, California, PROCEPT BioRobotics focuses on developing innovative technologies for men's health.

The company develops, manufactures, and sells the AquaBeam Robotic System and the HYDROS Robotic System. These image-guided, surgical robotic systems are utilized in minimally invasive urologic surgery, primarily for the treatment of benign prostatic hyperplasia (BPH) using Aquablation therapy. The HYDROS Robotic System represents the next-generation, AI-powered platform for delivering Aquablation therapy, which combines real-time imaging, personalized treatment planning, automated robotics, and a heat-free waterjet for targeted prostate tissue removal.

Larry L. Wood assumed the role of President and CEO on September 2, 2025, succeeding Dr. Reza Zadno. The company has recently expanded its global reach with the international launch of the HYDROS Robotic System in March 2026, following its FDA clearance in August 2024. PROCEPT BioRobotics reported strong financial performance in Q1 2026, with a 20% year-over-year revenue increase. The European Association of Urology guidelines also upgraded Aquablation therapy to a strong surgical recommendation for BPH in March 2026, reinforcing the company's market positioning as a leader in robotic solutions for urology.